CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
We found that CV comorbidities and use of medications with risk of QTc prolongation were common in patients with newly diagnosed HR + /HER2 - mBC. These factors should inform treatment decision-making (including CDK4/6 inhibitor selection), safety discussions with patients, and CV monitoring.
Authors
- Irene Arias
- Benjamin Li (ORCID: https://orcid.org/0000-0002-1783-7013)
- Avirup Guha (ORCID: https://orcid.org/0000-0003-0253-1174)
- Doris Makari
- Heather Moore
- Stella Stergiopoulos (ORCID: https://orcid.org/0000-0001-6868-0493)
- Michael G. Fradley (ORCID: https://orcid.org/0000-0001-8352-8975)
- Rachael McCaleb
- Susan Dent (ORCID: https://orcid.org/0000-0003-0291-5194)
Institutions
- Duke University (US)
- Pfizer (United States) (US)
- Augusta University (US)
- Hospital of the University of Pennsylvania (US)
- University of Rochester Medical Center (US)
- University of Rochester (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1186/s40959-025-00305-w
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Pfizer